➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Mallinckrodt
AstraZeneca
Baxter
Boehringer Ingelheim

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204223


Email this page to a colleague

« Back to Dashboard

NDA 204223 describes MORPHINE SULFATE, which is a drug marketed by Actavis Elizabeth, Impax Labs Inc, Nortec Dev Assoc, Par Pharm Inc, Teva Pharms Usa, Upsher Smith Labs, Hikma, Hospira, Hospira Inc, Icu Medical Inc, Intl Medication Sys, Specgx Llc, Watson Labs, Fresenius Kabi Usa, Akorn, Ani Pharms, Lannett Co Inc, Nostrum Labs Inc, Padagis Us, Pharm Assoc, Rhodes Pharms, Tris Pharma Inc, Vistapharm, Winder Labs Llc, Dava Pharms Inc, Epic Pharma Llc, Mayne Pharma Inc, Mylan Pharms Inc, Nesher Pharms, Novel Labs Inc, Sun Pharm Inds Ltd, Sun Pharm Industries, Vintage Pharms Llc, Alkem Labs Ltd, and Meridian Medcl Techn, and is included in fifty-eight NDAs. It is available from thirty-four suppliers. There are three patents protecting this drug. Additional details are available on the MORPHINE SULFATE profile page.

The generic ingredient in MORPHINE SULFATE is morphine sulfate. There are twenty-three drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.
Summary for 204223
Tradename:MORPHINE SULFATE
Applicant:Fresenius Kabi Usa
Ingredient:morphine sulfate
Patents:3
Formulation / Manufacturing:see details
Pharmacology for NDA: 204223
Mechanism of ActionFull Opioid Agonists
Medical Subject Heading (MeSH) Categories for 204223
Suppliers and Packaging for NDA: 204223
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MORPHINE SULFATE morphine sulfate SOLUTION;INTRAMUSCULAR, INTRAVENOUS 204223 NDA Fresenius Kabi USA, LLC 63323-451 63323-451-01 25 VIAL, SINGLE-DOSE in 1 BOX (63323-451-01) > 1 mL in 1 VIAL, SINGLE-DOSE (63323-451-00)
MORPHINE SULFATE morphine sulfate SOLUTION;INTRAMUSCULAR, INTRAVENOUS 204223 NDA Fresenius Kabi USA, LLC 63323-452 63323-452-01 25 VIAL, SINGLE-DOSE in 1 BOX (63323-452-01) > 1 mL in 1 VIAL, SINGLE-DOSE (63323-452-00)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAMUSCULAR, INTRAVENOUSStrength2MG/ML (2MG/ML)
Approval Date:Oct 30, 2013TE:RLD:Yes
Patent:⤷  Try it FreePatent Expiration:Mar 12, 2034Product Flag?YSubstance Flag?Delist Request?
Patent:⤷  Try it FreePatent Expiration:Mar 12, 2034Product Flag?Substance Flag?Delist Request?
Patented Use:MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
Patent:⤷  Try it FreePatent Expiration:Mar 12, 2034Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF PAIN

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Dow
McKesson
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.